The race to commercialize nuclear fusion will define the next era of geopolitical power. By one estimate, a single glass of fusion fuel carries the energy equivalent of one million gallons of oil, enough to power a home for more than 800 years.
A recent 60 Minutes segment gave the Cato Institute a platform to argue that America’s shipbuilding crisis proves protectionist industrial policy has failed. The opposite is true: the crisis is the product of four decades without an industrial policy.
Project Vault was developed to lend money to miners and entice investment in metals processing in order to build a strategic reserve of critical minerals to protect industry from supply shocks and price volatility.
A new Federal Reserve FEDS Note finds a systematic link between Chinese industrial policy interventions and export growth. The 15 most policy-targeted sectors accounted for 76% of the increase in China’s aggregate trade surplus from 2017 to 2024.
Last November, the White House released its National Security Strategy of the United States that laid out the Trump administration’s strategy for the Americas. In it, the strategy imperative for the region said that one of Washington’s key goals was to make sure the Americas remains “free of hostile foreign incursion or ownership of key assets,” and was supportive of U.S. access to critical supply chains. China wasn’t mentioned by name as the hostile adversary, but China is precisely who the White House had in mind.
Everyone agrees, in particular that reliance on China for key ingredients used to make medicines is risky; and everyone agrees that further up market – in advanced biotech – China is becoming an unmatched rival that could easily shrink America’s role in drug innovation.
Should Chinese organizations and individuals be allowed to donate to American colleges, and should their PhD students have access to scientific research grants? It’s not an easy question to answer.
It’s the second month in a row now that the U.S. Senate Special Committee on Aging has taken up the question of our woeful generics supply chain. This time, however, Ranking Member Kirsten Gillibrand (D-NY), started the hearing off by touching on a key topic in pharmaceuticals: the cost equation can no longer override the quality equation.
To reduce the deficit in a durable way, the United States must do more than tariff goods. It must tariff the money.
The development of GTAP-USL economic model marks another step forward in our efforts to make the GTAP more realistic and a better predictor of the real-world effects of trade policies or trade shocks. It’s critical to build models that provide a better understanding of how policies impact people, families, racial groups, gender, cities and regions. There is still more work to be done.
